PTC's novel cystic fibrosis drug shows benefit in Phase IIa
This article was originally published in Scrip
PTC Therapeutics' PTC124, a novel investigational treatment for cystic fibrosis, is able to reduce the ion transport abnormalities seen in the condition, Phase IIa results suggest.
You may also be interested in...
Amgen's investigational bone loss treatment denosumab more than halves osteoporosis patients' risk of new vertebral fractures, new data from a pivotal Phase III trial show.
Gilead Scienceswill need to conduct another clinical trial of its investigational cystic fibrosis treatment aztreonam lysine for inhalation before the drug can be approved, the US FDAhas said.